PreludeDx Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • PreludeDx's estimated annual revenue is currently $4.4M per year.(i)
  • PreludeDx's estimated revenue per employee is $77,500

Employee Data

  • PreludeDx has 57 Employees.(i)
  • PreludeDx grew their employee count by 27% last year.

PreludeDx's People

NameTitleEmail/Phone
1
CSOReveal Email/Phone
2
VP, Global Commercial MarketingReveal Email/Phone
3
VP, Business DevelopmentReveal Email/Phone
4
VP Scientific AffairsReveal Email/Phone
5
VP, Revenue CycleReveal Email/Phone
6
VP Strategic Marketing and Business DevelopmentReveal Email/Phone
7
VP, International SalesReveal Email/Phone
8
Director, National AccountsReveal Email/Phone
9
Director Business DevelopmentReveal Email/Phone
10
Senior Technical Director, OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is PreludeDx?

PreludeDx was founded to deliver actionable tools to manage early stage breast cancer. PreludeDx's first diagnostic test, DCISionRT is the result of over a decade of research and development focused on DCIS. PreludeDx began developing its DCIS test in 2009 after licensing technology from University of California, San Francisco. DCISionRT’s technology was designed from the beginning to address the critical question faced by patients with DCIS. What is my risk of recurrence and what treatment is appropriate?

keywords:N/A

N/A

Total Funding

57

Number of Employees

$4.4M

Revenue (est)

27%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.1M5716%N/A
#2
$6.3M572%N/A
#3
$6.9M570%N/A
#4
$14.3M574%N/A
#5
$3.5M572%N/A